These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

267 related items for PubMed ID: 22067206

  • 1. FDG-PET/CT in the diagnosis of recurrent breast cancer.
    Murakami R, Kumita S, Yoshida T, Ishihara K, Kiriyama T, Hakozaki K, Yanagihara K, Iida S, Tsuchiya S.
    Acta Radiol; 2012 Feb 01; 53(1):12-6. PubMed ID: 22067206
    [Abstract] [Full Text] [Related]

  • 2. Clinical utility of F-18 FDG PET/CT in recurrent breast carcinoma.
    Manohar K, Mittal BR, Senthil R, Kashyap R, Bhattacharya A, Singh G.
    Nucl Med Commun; 2012 Jun 01; 33(6):591-6. PubMed ID: 22334135
    [Abstract] [Full Text] [Related]

  • 3. ¹⁸F-Fluorodeoxyglucose positron emission tomography/computed tomography finds answers in cancer patients with increasing tumor markers and negative or equivocal conventional imaging modalities.
    Salem SS, Shahin MA.
    Nucl Med Commun; 2012 Mar 01; 33(3):313-21. PubMed ID: 22237387
    [Abstract] [Full Text] [Related]

  • 4. Clinical value of F18-fluorodeoxyglucose positron emission tomography-computed tomography in patients with non-small cell lung cancer after potentially curative surgery: experience with 241 patients.
    Kanzaki R, Higashiyama M, Maeda J, Okami J, Hosoki T, Hasegawa Y, Takami M, Kodama K.
    Interact Cardiovasc Thorac Surg; 2010 Jun 01; 10(6):1009-14. PubMed ID: 20197344
    [Abstract] [Full Text] [Related]

  • 5. F-18 fluorodeoxyglucose positron-emission tomography in the diagnosis of tumor recurrence and metastases in the follow-up of patients with breast carcinoma: a comparison to conventional imaging.
    Gallowitsch HJ, Kresnik E, Gasser J, Kumnig G, Igerc I, Mikosch P, Lind P.
    Invest Radiol; 2003 May 01; 38(5):250-6. PubMed ID: 12750613
    [Abstract] [Full Text] [Related]

  • 6. Role of 2-[18F] fluoro-2-deoxy-D-glucose-positron emission tomography/computed tomography in the post-therapy surveillance of breast cancer.
    Chang HT, Hu C, Chiu YL, Peng NJ, Liu RS.
    PLoS One; 2014 May 01; 9(12):e115127. PubMed ID: 25517451
    [Abstract] [Full Text] [Related]

  • 7. Assessment of multifocality and axillary nodal involvement in early-stage breast cancer patients using 18F-FDG PET/CT compared to contrast-enhanced and diffusion-weighted magnetic resonance imaging and sentinel node biopsy.
    Ergul N, Kadioglu H, Yildiz S, Yucel SB, Gucin Z, Erdogan EB, Aydin M, Muslumanoglu M.
    Acta Radiol; 2015 Aug 01; 56(8):917-23. PubMed ID: 25013091
    [Abstract] [Full Text] [Related]

  • 8. The role of 18F-FDG PET/CT in detecting colorectal cancer recurrence in patients with elevated CEA levels.
    Ozkan E, Soydal C, Araz M, Kir KM, Ibis E.
    Nucl Med Commun; 2012 Apr 01; 33(4):395-402. PubMed ID: 22367859
    [Abstract] [Full Text] [Related]

  • 9. Early diagnosis of recurrent breast cancer with FDG-PET in patients with progressive elevation of serum tumor markers.
    Suárez M, Pérez-Castejón MJ, Jiménez A, Domper M, Ruiz G, Montz R, Carreras JL.
    Q J Nucl Med; 2002 Jun 01; 46(2):113-21. PubMed ID: 12114874
    [Abstract] [Full Text] [Related]

  • 10. The utility of 18 F-FDG PET/CT for suspected recurrent breast cancer: impact and prognostic stratification.
    Cochet A, David S, Moodie K, Drummond E, Dutu G, MacManus M, Chua B, Hicks RJ.
    Cancer Imaging; 2014 Apr 22; 14(1):13. PubMed ID: 25608599
    [Abstract] [Full Text] [Related]

  • 11. Is combined 18F-fluorodeoxyglucose-positron emission tomography/computed tomography superior to positron emission tomography or computed tomography alone for diagnosis, staging and restaging of pancreatic lesions?
    Casneuf V, Delrue L, Kelles A, Van Damme N, Van Huysse J, Berrevoet F, De Vos M, Duyck P, Peeters M.
    Acta Gastroenterol Belg; 2007 Apr 22; 70(4):331-8. PubMed ID: 18330088
    [Abstract] [Full Text] [Related]

  • 12. Impact of ¹⁸F-FDG PET/CT for detecting recurrence of medullary thyroid carcinoma.
    Ozkan E, Soydal C, Kucuk ON, Ibis E, Erbay G.
    Nucl Med Commun; 2011 Dec 22; 32(12):1162-8. PubMed ID: 21946617
    [Abstract] [Full Text] [Related]

  • 13. Diagnosis of metastases from postoperative differentiated thyroid cancer: comparison between FDG and FLT PET/CT studies.
    Nakajo M, Nakajo M, Jinguji M, Tani A, Kajiya Y, Tanabe H, Fukukura Y, Nakabeppu Y, Koriyama C.
    Radiology; 2013 Jun 22; 267(3):891-901. PubMed ID: 23468571
    [Abstract] [Full Text] [Related]

  • 14. Diagnostic accuracy of dual-time-point 18F-FDG PET/CT for the detection of axillary lymph node metastases in breast cancer patients.
    Hahn S, Hecktor J, Grabellus F, Hartung V, Pöppel T, Kimmig R, Forsting M, Antoch G, Heusner TA.
    Acta Radiol; 2012 Jun 01; 53(5):518-23. PubMed ID: 22547387
    [Abstract] [Full Text] [Related]

  • 15. Role of FDG PET-CT in detecting recurrence in patients with uterine sarcoma: comparison with conventional imaging.
    Sharma P, Kumar R, Singh H, Jeph S, Sharma JB, Jain SK, Sharma DN, Bal C, Malhotra A.
    Nucl Med Commun; 2012 Feb 01; 33(2):185-90. PubMed ID: 22107993
    [Abstract] [Full Text] [Related]

  • 16. Prospective evaluation of 68Ga-DOTA-NOC PET-CT in patients with recurrent medullary thyroid carcinoma: comparison with 18F-FDG PET-CT.
    Naswa N, Sharma P, Suman Kc S, Lata S, Kumar R, Malhotra A, Bal C.
    Nucl Med Commun; 2012 Jul 01; 33(7):766-74. PubMed ID: 22531829
    [Abstract] [Full Text] [Related]

  • 17. Evaluation of PET and MR datasets in integrated 18F-FDG PET/MRI: A comparison of different MR sequences for whole-body restaging of breast cancer patients.
    Grueneisen J, Sawicki LM, Wetter A, Kirchner J, Kinner S, Aktas B, Forsting M, Ruhlmann V, Umutlu L.
    Eur J Radiol; 2017 Apr 01; 89():14-19. PubMed ID: 28267530
    [Abstract] [Full Text] [Related]

  • 18. High incidence of peritoneal implants in recurrence of intra-abdominal cancer revealed by 18F-FDG PET/CT in patients with increased tumor markers and negative findings on conventional imaging.
    Panagiotidis E, Datseris IE, Exarhos D, Skilakaki M, Skoura E, Bamias A.
    Nucl Med Commun; 2012 Apr 01; 33(4):431-8. PubMed ID: 22293498
    [Abstract] [Full Text] [Related]

  • 19. Utility of 18-fluorodeoxyglucose positron emission/computed tomography in the management of recurrent colorectal cancer.
    Liong SY, Kochhar R, Renehan AG, Manoharan P.
    ANZ J Surg; 2012 Oct 01; 82(10):729-36. PubMed ID: 22989147
    [Abstract] [Full Text] [Related]

  • 20. The role of FDG-PET/CT in suspected recurrence of breast cancer.
    Radan L, Ben-Haim S, Bar-Shalom R, Guralnik L, Israel O.
    Cancer; 2006 Dec 01; 107(11):2545-51. PubMed ID: 17063499
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.